Keywords: Roche, Rituxan, Rare diseases, FDA, USA, Wegener's grannulomatosis, Microscopic polyanitiis

Roche gets FDA OK for use of Rituxan to treat two rare disorders

Article | 21 April 2011

Print This

The US Food and Drug Administration yesterday approved Swiss drug major Roche (ROG: SIX) subsidiary Genentech’s Rituxan (rituximab), ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in